My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

796.55 -4.46 (-0.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

58 59 Next >

Healthcare Portfolio Focus Stocks ↗

October 16, 2023

The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.

Via Talk Markets

Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗

October 16, 2023

Via Benzinga

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗

October 16, 2023

These two large-cap biopharma companies could have more room to run.

Via The Motley Fool

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

October 15, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points ↗

October 14, 2023

Broadcom and Arista lead five stocks sporting a flat base.

Via Investor's Business Daily

Topics Artificial Intelligence

The Latest Analyst Ratings for Regeneron Pharmaceuticals ↗

October 11, 2023

Via Benzinga

Down 45%, Is Intellia a Buy? ↗

October 10, 2023

Intellia's operating in the high-growth field of gene editing.

Via The Motley Fool

Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up ↗

October 09, 2023

Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.

Via Talk Markets

P/E Ratio Insights for Regeneron Pharmaceuticals ↗

October 06, 2023

Via Benzinga

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

October 05, 2023

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

October 04, 2023

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity ↗

October 03, 2023

Via Benzinga

Examining the Quality Attributes of NASDAQ:REGN. ↗

September 22, 2023

Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN).

Via Chartmill

This Market-Beating Stock Just Gave Investors More Reasons to Invest ↗

October 05, 2023

There is a lot going the way of this biotech giant right now.

Via The Motley Fool

Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close) ↗

October 05, 2023

This stock puts the "big" in big pharma after massive gains in recent years.

Via The Motley Fool

MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer ↗

October 03, 2023

MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S.

Via Benzinga

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

October 03, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 02, 2023

Via Benzinga

Analyst Expectations for Regeneron Pharmaceuticals's Future ↗

September 21, 2023

Via Benzinga

Stock Split Watch: Is Regeneron Pharmaceuticals Next? ↗

September 30, 2023

If the biotech does split its stock, it will be a first for the company.

Via The Motley Fool

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

September 29, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

September 28, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 28, 2023

Via Benzinga

Three Of Our Top Picks For Your Healthcare Portfolio ↗

September 26, 2023

Amidst macro uncertainty, healthcare stocks should outperform.

Via Talk Markets

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

September 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

September 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost ↗

September 20, 2023

A higher-dose version of Eylea will help the company fight off competition and increase revenue.

Via The Motley Fool

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.